الولايات المتحدة · منصات وبيانات · MarketBeat

Coherus Oncology Reports 89% Response Rate in Early ESCC Study

نشره MarketBeat · الولايات المتحدة منذ 2 س

Coherus Oncology (NASDAQ:CHRS) presented interim clinical data for tagmokitug, an investigational therapy designed to target CCR8-positive regulatory T cells, in several…

اقرأ المقال كاملًا على MarketBeat سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.marketbeat.com)

يستحق القراءة أيضًا

Seeking Alpha

Glaukos projects $1B 2027 revenue as it raises 2026 net sales guidance to $775M-$785M

The Motley Fool

Small-Cap Stocks Just Did Something They Haven't Done Since 2018. Is It Finally Time to Buy?

MarketWatch

Coherus Oncology Reports 89% Response Rate in Early ESCC Study

مشاركة

يستحق القراءة أيضًا

Glaukos projects $1B 2027 revenue as it raises 2026 net sales guidance to $775M-$785M

Small-Cap Stocks Just Did Something They Haven't Done Since 2018. Is It Finally Time to Buy?

Why Alphabet’s stock could see its worst drop in years after the latest results

Airline groups urge US CDC to reconsider Ebola declaration requirements

Anvil Research Labs CEO flags buy now, pay later’s hidden debt risk

Oracle Forecasts $30B Cash Flow By FY29, Helping Calm AI Capex Concerns, Pushing ORCL Stock To Its Best Day In Five Months